Hiroki Nishikawa
Overview
Explore the profile of Hiroki Nishikawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
337
Citations
3088
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nishikawa H, Kim S, Asai A
Int J Mol Sci
. 2025 Feb;
26(3).
PMID: 39940810
Myokine is a general term for hormones, peptides, and other substances secreted by skeletal muscle. Myokine has attracted much attention in recent years as a key substance for understanding the...
12.
Ogura T, Uba Y, Kanadani T, Bessho K, Nishikawa H
Endoscopy
. 2025 Feb;
57(S 01):E99-E100.
PMID: 39909411
No abstract available.
13.
Hiraoka A, Kudo M, Tada T, Hatanaka T, Kakizaki S, Kariyama K, et al.
Oncology
. 2025 Feb;
:1-23.
PMID: 39900019
Background/aim: Rapid development of systemic treatments has resulted in improved prognosis for unresectable hepatocellular carcinoma (uHCC) patients. Since immune therapy shows a favorable therapeutic efficacy, use of tumor markers as...
14.
Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, et al.
J Gastroenterol Hepatol
. 2025 Jan;
PMID: 39844393
Background And Aim: To assess the relationship between survival outcomes and subtypes of radiological progressive disease (PD) in patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (Atezo/Bev). Methods:...
15.
Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, et al.
Cancer Med
. 2025 Jan;
14(2):e70618.
PMID: 39840727
Aim: This study aims to investigate the clinical utility of the derived neutrophil-to-lymphocyte ratio (dNLR) and the Geriatric Nutritional Risk Index (GNRI) in predicting treatment outcomes for patients with unresectable...
16.
Hachisuka S, Kitano T, Kitagawa D, Murata M, Onishi M, Mori T, et al.
Diagn Microbiol Infect Dis
. 2025 Jan;
111(3):116688.
PMID: 39832478
The etiology of Kawasaki disease (KD) has not yet been completely elucidated. We evaluated the temporal association between respiratory pathogens and KD incidence and the association between respiratory pathogens and...
17.
Sugawara N, Iwatsubo T, Mori Y, Takayama K, Sasaki S, Nakajima N, et al.
DEN Open
. 2025 Jan;
5(1):e70056.
PMID: 39807430
Endoscopic injection sclerotherapy (EIS) is a useful prophylactic hemostatic procedure for esophageal varices. However, injecting sclerosing agents into blood vessels is technically challenging and often ineffective. Gel-immersion EIS (GI-EIS) may...
18.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al.
J Gastroenterol Hepatol
. 2025 Jan;
PMID: 39762722
Aim: This study aimed to compare the prognostic performance of the risk models for patients with hepatocellular carcinoma (HCC) receiving atezolizumab and bevacizumab (Atez/Bev) as first-line treatment. Methods: Among 449...
19.
Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, et al.
Sci Rep
. 2025 Jan;
15(1):72.
PMID: 39747852
In the current era of immune therapy, lenvatinib (LEN) continues to be vital for treating unresectable hepatocellular carcinoma (uHCC) patients. This study investigates the importance of nutritional status in the...
20.
Matsui M, Fukuda A, Onishi S, Ushiro K, Nishikawa T, Asai A, et al.
In Vivo
. 2024 Dec;
39(1):381-389.
PMID: 39740891
Background/aim: To elucidate the relationship between metabolic syndrome (Mets) and somatic composition [fat mass, fat-free (FF) mass, and fat to fat-free (F-FF) ratio] among health checkup recipients (7,776 males and...